PROK 250117 5.00C (PROK250117C5000) Stock Options, News & Quotes

US OptionsDetailed Quotes

PROK250117C5000

Watchlist

0.10
0.000.00%

15min DelayClose Jan 17 16:00 ET

0.00High0.00Low

Intraday

5D
Daily

News

Cautiously Optimistic: ProKidney's Hold Rating Amid Accelerated Pathway and Trial Developments
TipRanksJan 15 20:17 ET · Ratings
ProKidney to Present at the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswireJan 7 07:30 ET
One ProKidney Insider Raised Their Stake In The Previous Year
Yahoo FinanceJan 5 07:56 ET
ProKidney to Participate in Two Upcoming Conferences: Evercore HealthCONx Conference and the Citi Global Healthcare Conference
GlobeNewswireNov 26, 2024 07:30 ET
ProKidney (NASDAQ:PROK) Is In A Good Position To Deliver On Growth Plans
Simply Wall StNov 21, 2024 06:08 ET
Morgan Stanley Maintains ProKidney(PROK.US) With Hold Rating, Maintains Target Price $3
Moomoo NewsNov 13, 2024 05:38 ET · Ratings

Comments

MARKET-TEST-DUMMY

Dec 26, 2024 10:26

Any news expected here

$ProKidney (PROK.US)$ anytime soon. I know someone following it.

MARKET-TEST-DUMMY

Dec 5, 2024 18:37

👁

$ProKidney (PROK.US)$

Jaguar8

Nov 12, 2024 06:31

NEWS ER

$ProKidney (PROK.US)$
ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting
Positive
FDA confirmation that PROACT 1 Phase 3 study could be sufficient for full regulatory approval
Accelerated approval pathway available with eGFR slope as surrogate endpoint
Strong cash position of $406.8 million, supporting operations into 2027
Reduced R&D expenses by $0.9 million year-over-year
Slight improvement...

Jaguar8

Oct 22, 2024 16:50

Put alert 13Gs filed aftermarket

$ProKidney (PROK.US)$

Trytosaveabit

Oct 22, 2024 14:46

New 13G/A

$ProKidney (PROK.US)$ ProKidney | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Aaron Cowen(10.47%),Suvretta Capital Management, LLC(9.8%), etc.
SEC· 11 mins ago